RISK OF RECURRENCE AMONG PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE, EARLY BREAST CANCER RECEIVING ADJUVANT ENDOCRINE THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS

被引：0
|
作者：
Ramirez, Oliva A. [1 ]
Law, E. H. [2 ]
Cueto, J. [2 ]
Salvo, E. M. [1 ]
Situ, A. [1 ]
Samjoo, I. A. [1 ]
机构：
[1] EVERSANA, Burlington, ON, Canada
[2] Pfizer Inc, New York, NY USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN43
引用
收藏
页码：S429 / S429
页数：1
相关论文
共 50 条
  • [1] Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis
    Salvo, Elizabeth M.
    Ramirez, Abril Oliva
    Cueto, Jenilee
    Law, Ernest H.
    Situ, Aaron
    Cameron, Chris
    Samjoo, Imtiaz A.
    BREAST, 2021, 57 : 5 - 17
  • [2] HEALTH UTILITIES FOR PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER: A SYSTEMATIC LITERATURE REVIEW
    da Silva, Aniceto C.
    Cueto, J.
    Salvo, E. M.
    Samjoo, I. A.
    Law, E. H.
    VALUE IN HEALTH, 2020, 23 : S445 - S445
  • [3] Efficacy and safety of neoadjuvant therapy for HR-positive/HER2-negative early breast cancer: a Bayesian network meta-analysis
    Chen, Ruiliang
    Yu, Yushuai
    Zhang, Jie
    Song, Chuangui
    Wang, Chuan
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (07) : 599 - 611
  • [4] Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials
    Gao, Hong-Fei
    Lin, Ying-Yi
    Zhu, Teng
    Ji, Fei
    Zhang, Liu-Lu
    Yang, Ci-Qiu
    Yang, Mei
    Li, Jie-Qing
    Cheng, Min-Yi
    Wang, Kun
    BREAST, 2021, 59 : 165 - 175
  • [5] Ribociclib in HR-positive, HER2-negative breast cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2016, 17 (11): : E482 - E482
  • [6] Systemic Therapy of HR-positive, HER2-negative metastatic Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (03) : 257 - 257
  • [7] Adjuvant chemotherapy in elderly patients with HER2-negative early breast cancer: A systematic review and meta-analysis
    Petrelli, Fausto
    Dottorini, Lorenzo
    Sarno, Italo
    Di Menna, Giandomenico
    Angeli, Irene
    Moleri, Giovanna
    Battaiotto, Elena
    Luciani, Andrea
    TUMORI JOURNAL, 2025,
  • [8] Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis
    Hasson, S. Peleg
    Brezis, M. R.
    Shachar, E.
    Shachar, S. S.
    Wolf, I
    Sonnenblick, A.
    ESMO OPEN, 2021, 6 (02)
  • [9] Adjuvant endocrine therapy in HER2-positive breast cancer patients: Systematic review and meta-analysis
    Hasson, S. Peleg
    Shachar, E.
    Brezis, M.
    Shachar, S.
    Wolf, I.
    Sonnenblick, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S43 - S43
  • [10] The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis
    Huang, Xiewei
    Yu, Yushuai
    Luo, Shiping
    Fu, Wenfen
    Zhang, Jie
    Song, Chuangui
    BMC CANCER, 2024, 24 (01)
12345